Abstract: A method for the stabilization of a phospholipidic composition as well as a method for the production of a stabilized phospholipidic composition comprising at least one phospholipide as well as a stabilizer are described, whereby in the claimed methods at least one phospholipide is mixed with a stabilizer on the basis of phytic acid, of a salt of the phytic acid and/or of a phytic acid derivative.

Abstract: A phospholipidic composition provides resistance against rancidity and the development of undesirable odors. The composition includes at least one phospholipid and a stabilizer. The stabilizer is ground parts and/or an extract of a grain. The composition is prepared by simple and reliable methods of production.

Abstract: A pharmaceutical, orally applicable composition is disclosed, whereby the composition contains at least one antacid active substance as well as more than 45% by weight of a sugar and/or sugar alcohol and between 12% and 35% by weight of water. The composition has a liquid or a semisolid consistency and is substantially free of preservatives.

Abstract: A method for the stabilization of a phospholipidic composition as well as a method for the production of a stabilized phospholipidic composition comprising at least one phospholipide as well as a stabilizer are described, whereby in the claimed methods at least one phospholipide is mixed with a stabilizer on the basis of phytic acid, of a salt of the phytic acid and/or of a phytic acid derivative.

Abstract: A sale unit for the parenteral application of liquid pharmaceutical products by the user is described, whereby the unit comprises at least one cannula, a device to emit a given liquid amount of the pharmaceutical product in single doses, as well as at least one vessel filled with the pharmaceutical product, the vessel being arranged within the device and emptied in single doses by means of the device, and whereby each single dose corresponds to the given liquid amount of the pharmaceutical product.

Abstract: A pharmaceutical, orally applicable composition is described, whereby the solid composition contains at least one antacid active ingredient and/or at least one H.sub.2 -antagonist, at least one disintegrant, as well as at least one usual pharmaceutical additional ingredient. Furthermore said composition contains at least one ingredient that accelerates the decomposition of said composition in the mouth or in a liquid, whereby said ingredient is a water-soluble amino acid, a water-soluble amino acid derivative and/or a water-soluble amino acid salt.

Abstract: A pharmaceutical, orally applicable composition is described, whereby the solid composition contains at least one active ingredient, at least one disintegrant, as well as at least one usual pharmaceutical additional ingredient. Furthermore said composition contains at least one ingredient that accelerates the decomposition of said composition in the mouth or in a liquid, whereby said ingredient is a water-soluble amino acid, a water-soluble amino acid derivative and/or a water-soluble amino acid salt.

Abstract: The invention pertains to a method and device for separating a mixture having at least two components, wherein a separation phase is impacted by the mixture to be separated and then the separation phase loaded with the mixture is eluted with at least one fluid. The separation phase is transported from a first station, at which it is introducted with the mixture for separation, to at least a second station, at which the separation phase is eluted with the at least one fluid.

Abstract: A pharmaceutical, oral composition of a liquid to semisolid consistency is disclosed, wherein the composition, substantially free of preservatives, contains at least one antacid active substance as well as more than 45% by weight, a sugar and/or sugar alcohol, relative to the ready-to-use composition, and up to 40% by weight, a pharmaceutically harmless solvent, relative to the ready-to-use composition.

Abstract: A method of inhibiting oxidation of products containing unsaturated fatty acids and their derivatives comprises treating the unsaturated fatty acids and their derivatives with N-acylphosphatidylethanolamines. Preferred N-acylphosphatidylethanolamines are N-acetylphosphatidylethanolamine and N-oleoylphosphatidylethanolamine.

Abstract: 2-Phenyl-1,2-benzisoselenazol-3(2H)-one(Ebselen) is capable of reducing the cisplatin-induced nephrotoxicity and neurotoxcity during cytostatic treatment.